Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vistagen Therapeutics (VTGN) EBITDA (2017 - 2025)

Historic EBITDA for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to -$18.9 million.

  • Vistagen Therapeutics' EBITDA fell 3404.26% to -$18.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$67.0 million, marking a year-over-year decrease of 4176.31%. This contributed to the annual value of -$51.4 million for FY2025, which is 7510.05% down from last year.
  • According to the latest figures from Q4 2025, Vistagen Therapeutics' EBITDA is -$18.9 million, which was down 3404.26% from -$19.4 million recorded in Q3 2025.
  • Vistagen Therapeutics' 5-year EBITDA high stood at -$6.2 million for Q1 2021, and its period low was -$19.8 million during Q2 2022.
  • Its 5-year average for EBITDA is -$12.4 million, with a median of -$12.5 million in 2021.
  • As far as peak fluctuations go, Vistagen Therapeutics' EBITDA plummeted by 28862.07% in 2021, and later surged by 6508.89% in 2023.
  • Quarter analysis of 5 years shows Vistagen Therapeutics' EBITDA stood at -$10.5 million in 2021, then grew by 7.33% to -$9.8 million in 2022, then surged by 34.98% to -$6.4 million in 2023, then crashed by 122.05% to -$14.1 million in 2024, then plummeted by 34.04% to -$18.9 million in 2025.
  • Its EBITDA stands at -$18.9 million for Q4 2025, versus -$19.4 million for Q3 2025 and -$15.1 million for Q2 2025.